Skip to main content
. 2023 Sep 26;10(3):37–60. doi: 10.15586/jkcvhl.v10i3.295

Table 4:

Renal medullary and collecting duct histology.

Agent (trial, year) Phase N per group Primary endpoint ORR, % (95% CI) mPFS, months (95% CI) OS, months (95% CI)
Gemcitabine + cisplatin or carboplatin (2007)(75) II 23 Collecting ducts ORR 26 (8–44) 7.1 (3–11.3) 10.5 (3.8–71.1)
Cabozantinib
(BONSAI, 2022)(78)
II 23 Collecting ducts ORR 35 (16–57) 4 (3–13) 7 (3–31)

ORR: overall response rate, mPFS: median progression-free survival, OS: overall survival.